Value
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 2.2 |
| P/S | 8.1 |
| EV/EBITDA | 2.1 |
| Fwd P/E | 6.8 |
| PEG | 5.8 |
| Analyst target | 5.0 |
- ▸Forward P/E: 18.6x
- ▸PEG: 1.29
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Alcon is a medical device maker with a 9/9 Piotroski score and 198% cash conversion, but the price is within 3.3% of the analyst target, revenue growth is modest, and the stock is an overbought rally inside a downtrend.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
| Pillar | Expectation | Trend |
|---|---|---|
Free cash flow is 198% of net income and the Piotroski F-Score is a perfect 9/9, indicating high earnings quality. Quality breakdown | Free cash flow stays above 100% of net income and the F-Score stays at 8 or higher. | →Stable |
| CounterROE (component 1.0/10) and net margin (3.0/10) are weak, so strong cash conversion sits on low reported profitability. | ||
The $71.45 price is only 3.3% below the $73.79 analyst target against 13.1% downside to the stop, a reward-to-risk of 0.25. Estimated upside | Analyst targets rise above $80, or the price pulls back toward the $68.45 stop level. | →Stable |
| CounterAnalysts have a favorable rating of 7.33/10, and targets can rise if sales and margins improve. | ||
Revenue growth scores 4.7/10 and forward P/E is 18.1x with a PEG of 1.29, which prices a steady but not fast-growing business. Valuation breakdown | Revenue growth accelerates so the PEG falls below 1.2. | ↓Deteriorating |
| CounterWith modest growth and a mid-teens multiple, there is little valuation cushion if growth slows. | ||
The RSI of 76 marks an overbought rally while the price remains below a 200-day average falling 2.7% over 30 days. Momentum breakdown | Price reclaims the 200-day average and the average slope turns flat. | ↑Improving |
| CounterRising on-balance volume and an improving MACD suggest a recovery, so the rally may continue. | ||
The stock is labeled a dividend aristocrat with a safety component of 8.5/10, but the yield is only 0.5%. Catalyst breakdown | The dividend is maintained or raised over the next 12 months. | ↑Improving |
| CounterA 0.5% yield provides little income to cushion a price decline. | ||
CounterROE (component 1.0/10) and net margin (3.0/10) are weak, so strong cash conversion sits on low reported profitability.
CounterAnalysts have a favorable rating of 7.33/10, and targets can rise if sales and margins improve.
CounterWith modest growth and a mid-teens multiple, there is little valuation cushion if growth slows.
CounterRising on-balance volume and an improving MACD suggest a recovery, so the rally may continue.
CounterA 0.5% yield provides little income to cushion a price decline.
| Component | Sub-score |
|---|---|
| P/E | 2.2 |
| P/S | 8.1 |
| EV/EBITDA | 2.1 |
| Fwd P/E | 6.8 |
| PEG | 5.8 |
| Analyst target | 5.0 |
| Component | Sub-score |
|---|---|
| ROE | 1.0 |
| ROA | 1.9 |
| Gross margin | 7.4 |
| Op margin | 5.9 |
| Net margin | 3.0 |
| Current ratio | 7.3 |
| FCF quality | 10.0 |
| Moat | 7.2 |
| Piotroski F | 10.0 |
| Component | Sub-score |
|---|---|
| Rev growth | 4.7 |
| Component | Sub-score |
|---|---|
| RSI | 4.1 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 4.5 |
| Component | Sub-score |
|---|---|
| Analyst rating | 7.3 |
| Price target | 6.9 |
| erm sentiment | 5.5 |
| Component | Sub-score |
|---|---|
| value rank | 2.9 |
| quality rank | 5.4 |
| growth rank | 5.4 |
| Component | Sub-score |
|---|---|
| bollinger | 1.6 |
| support resistance | 1.5 |
| 52w position | 6.6 |
| Component | Sub-score |
|---|---|
| days to cover | 0.0 |
| volatility | 7.2 |
| put call | 10.0 |
| implied vol | 5.3 |
| max pain risk | 3.0 |
| beta | 8.7 |
| debt equity | 9.0 |
| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 4.6 |
| dividend safety | 8.5 |
Maintain position. Not compelling to add more.
L4:PATH_F_HOLDSetupRecovery — Death cross but MACD improving, RSI 78
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:7.2>=5.5. Top dim: Momentum at 7.2; weakest: Technical at 3.2. No conviction either direction.
The strongest dimensions are Momentum at 7.2, Sentiment at 6.7, and Risk (lower is worse) at 6.2; the weakest are Technical at 3.2, Growth at 4.7, and Peer rank at 5.0. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.14 and an engine sizing output of AVOID.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
Trip ifFree cash flow to net income falls below 100% from current 198%.
Trip ifShare price rises above $78 while the analyst target stays below $75, a gap of more than 4%.
Trip ifRevenue growth component stays below 3.0 for 2 consecutive quarterly updates.
Trip ifShare price falls below the $68.45 stop level, a drop of more than 4.2%.
Trip ifDividend yield falls below 0.3% from current 0.5%.